To further test our hypothesis that PIK3CA mutation was responsible for the resistance to Trastuzumab therapy in a HER-2 positive esophageal PDECX model, we performed an anti-tumor efficacy combination study using Trastuzumab and the small molecule AKT inhibitor, AZD5363 [14]. Here, AKT1 is linked to neoplasm.